**Introduction**

- Mpx is responsible for a recent global outbreak with over 80,000 cases of infection to date, which has disproportionately affected gay and bisexual individuals.
- Mpx can cause serious illness, including painful mucosal lesions, superinfections, and ocular disease.
- Data on the efficacy of therapy with tecovirimat for mpx is limited.
- We describe the clinical characteristics and course of individuals diagnosed with mpx in a large New York City (NYC) health system who were prescribed tecovirimat.

**Methods**

- This is a retrospective study describing the clinical features of persons with mpx and the clinical outcomes amongst those who received tecovirimat per CDC eIND protocol (typical duration of 14-days).
- Data was obtained via chart review of patients prescribed tecovirimat in the Mount Sinai Health System in NYC during 7/1/2022 - 10/1/2022.
- Demographics, medical history, clinical and laboratory characteristics and outcomes were collected at baseline and post treatment.

**Results**

<table>
<thead>
<tr>
<th>Top Presenting Symptoms</th>
<th>Hemorhoids</th>
<th>Dysuria or difficulty urinating</th>
<th>Headache</th>
<th>Fatigue</th>
<th>Myalgias</th>
<th>Pain with swallowing or</th>
<th>Lymphadenopathy</th>
<th>Fever and/or chills</th>
<th>Pain with deflection</th>
<th>Non-specific Pain</th>
<th>Skin Rash</th>
</tr>
</thead>
<tbody>
<tr>
<td>Percent (%)</td>
<td>10%</td>
<td>12%</td>
<td>16%</td>
<td>26%</td>
<td>26%</td>
<td>34%</td>
<td>35%</td>
<td>45%</td>
<td>56%</td>
<td>58%</td>
<td>76%</td>
</tr>
</tbody>
</table>

**Lesions by Anatomical Location**

<table>
<thead>
<tr>
<th>Location</th>
<th>Skin (98%)</th>
<th>Anal (88%)</th>
<th>Mucoosal (71%)</th>
<th>Eye (4%)</th>
</tr>
</thead>
</table>

**Clinical Characteristics of People With HIV**

- **HIV or other immunomodulatory conditions**.
- **Lesions and pain fully resolved on treatment day #** — day (median) 10
- **Lessons or pain first started to improve on treatment day #** — day (median) 3
- **Superimposed infections in comparison to those with HIV compared to immunocompetent patients**.
- **Immunocompromising conditions, with most hospitalized patients having HIV** and a third determined to have severe immunocompromise.

**Conclusions**

- **Mpx disproportionally affects gay individuals and MSM**.
- **Nearly all patients eventually demonstrated recovery**.
- **The majority of mpx-related hospitalizations occurred in patients with underlying immunocompromising conditions, with most hospitalized patients having HIV** and a third determined to have severe immunocompromise.

**Acknowledgements**

I want to thank all my faculty advisors for their guidance and mentorship, as well as the clinicians who evaluated and care for these patients.